MedTrace Logo

An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)

NCT07750990 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-06

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD.

Participants who completed other S-606001 studies (for example, NCT07123155), including participants in a S-606001 study whose allocated arm was terminated by the sponsor and who are willing to participate in this study, will be enrolled globally.

Conditions

Interventions

DRUG

S-606001

S-606001 will be administered orally.

DRUG

ERT

ERT will be administered as an intravenous infusion.

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Principal Investigators

  • Medical Director · Shionogi Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-08-31
Completion
2028-08-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07750990 on ClinicalTrials.gov